Mary Schroth, Jennifer Deans, Kapil Arya, Diana Castro, Darryl C De Vivo, Melissa A Gibbons, Cristian Ionita, Nancy L Kuntz, Arpita Lakhotia, Erin Neil Knierbein, Mariacristina Scoto, Thomas Sejersen, Laurent Servais, Cuixia Tian, Megan A Waldrop, Juan F Vázquez-Costa
{"title":"Spinal Muscular Atrophy Update in Best Practices: Recommendations for Diagnosis Considerations.","authors":"Mary Schroth, Jennifer Deans, Kapil Arya, Diana Castro, Darryl C De Vivo, Melissa A Gibbons, Cristian Ionita, Nancy L Kuntz, Arpita Lakhotia, Erin Neil Knierbein, Mariacristina Scoto, Thomas Sejersen, Laurent Servais, Cuixia Tian, Megan A Waldrop, Juan F Vázquez-Costa","doi":"10.1212/CPJ.0000000000200310","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Spinal muscular atrophy (SMA) is an autosomal recessive progressive neurodegenerative primary motor neuron disorder caused by biallelic variants of the survival motor neuron 1 (<i>SMN1</i>) gene. The most recent SMA best practice recommendations were published in 2018 shortly after the approval of the first SMN-enhancing treatment. The availability of disease-modifying therapies for 5q SMA and implementation of SMA newborn screening (NBS) has led to urgency to update the SMA best practice recommendations for diagnosis and to reevaluate the current classification of SMA. In addition, the availability of disease-modifying therapies has opened the door to explore improved diagnosis of adult-onset SMA.</p><p><strong>Methods: </strong>A systematic literature review was conducted on SMA NBS. An SMA working group of American and European health care providers developed recommendations through a modified Delphi technique with serial surveys and virtual meeting feedback on SMA diagnosis to fill information gaps for topics with limited evidence. A community working group of an individual with SMA and caregivers provided insight and perspective on SMA diagnosis and support through a virtual meeting to guide recommendations.</p><p><strong>Results: </strong>The health care provider working group achieved consensus that SMA NBS is essential to include in the updated best practice for SMA diagnosis (100%). Recommendations for the following are described: characterizing NBS-identified infants before treatment; minimum recommendations for starting or offering SMA NBS in a state or country; recommendations for activities and services to be provided by an SMA specialty care center accepting SMA NBS referrals; and recommendations for partnership with individuals with SMA and caregivers to support NBS-identified infants and their caregivers. Limited data are available to advance efficient diagnosis of adult-onset SMA.</p><p><strong>Discussion: </strong>Updating best practice recommendations for SMA diagnosis to include SMA NBS implementation is essential to advancing care for individuals with SMA. In addition to testing, processes for the efficient management of positive newborn screen with access to knowledgeable and skilled health care providers and access to treatment options is critical to successful early diagnosis. Additional evidence is required to improve adult-onset SMA diagnosis.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11195435/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology. Clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/CPJ.0000000000200310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Spinal muscular atrophy (SMA) is an autosomal recessive progressive neurodegenerative primary motor neuron disorder caused by biallelic variants of the survival motor neuron 1 (SMN1) gene. The most recent SMA best practice recommendations were published in 2018 shortly after the approval of the first SMN-enhancing treatment. The availability of disease-modifying therapies for 5q SMA and implementation of SMA newborn screening (NBS) has led to urgency to update the SMA best practice recommendations for diagnosis and to reevaluate the current classification of SMA. In addition, the availability of disease-modifying therapies has opened the door to explore improved diagnosis of adult-onset SMA.
Methods: A systematic literature review was conducted on SMA NBS. An SMA working group of American and European health care providers developed recommendations through a modified Delphi technique with serial surveys and virtual meeting feedback on SMA diagnosis to fill information gaps for topics with limited evidence. A community working group of an individual with SMA and caregivers provided insight and perspective on SMA diagnosis and support through a virtual meeting to guide recommendations.
Results: The health care provider working group achieved consensus that SMA NBS is essential to include in the updated best practice for SMA diagnosis (100%). Recommendations for the following are described: characterizing NBS-identified infants before treatment; minimum recommendations for starting or offering SMA NBS in a state or country; recommendations for activities and services to be provided by an SMA specialty care center accepting SMA NBS referrals; and recommendations for partnership with individuals with SMA and caregivers to support NBS-identified infants and their caregivers. Limited data are available to advance efficient diagnosis of adult-onset SMA.
Discussion: Updating best practice recommendations for SMA diagnosis to include SMA NBS implementation is essential to advancing care for individuals with SMA. In addition to testing, processes for the efficient management of positive newborn screen with access to knowledgeable and skilled health care providers and access to treatment options is critical to successful early diagnosis. Additional evidence is required to improve adult-onset SMA diagnosis.
背景和目的:脊髓性肌萎缩症(SMA)是一种常染色体隐性进行性神经退行性原发性运动神经元疾病,由存活运动神经元1(SMN1)基因的双倍变异引起。在首个SMN增强疗法获批后不久,2018年发布了最新的SMA最佳实践建议。随着 5q SMA 疾病修饰疗法的出现以及 SMA 新生儿筛查(NBS)的实施,迫切需要更新 SMA 诊断最佳实践建议,并重新评估当前的 SMA 分类。此外,疾病改变疗法的出现也为探索改进成年型 SMA 的诊断打开了大门:方法:对 SMA NBS 进行了系统的文献回顾。一个由美国和欧洲医疗保健提供者组成的 SMA 工作组通过改良的德尔菲(Delphi)技术,对 SMA 诊断进行连续调查和虚拟会议反馈,以填补证据有限的主题的信息空白,从而提出建议。由一名 SMA 患者和护理人员组成的社区工作组通过虚拟会议提供有关 SMA 诊断和支持的见解和观点,以指导建议的制定:结果:医疗服务提供者工作组达成了共识,即 SMA NBS 必须纳入最新的 SMA 诊断最佳实践(100%)。该工作组提出了以下建议:在治疗前确定 NBS 鉴定婴儿的特征;在一个州或国家启动或提供 SMA NBS 的最低建议;接受 SMA NBS 转介的 SMA 专科护理中心应提供的活动和服务建议;与 SMA 患者和护理人员合作以支持 NBS 鉴定婴儿及其护理人员的建议。现有数据有限,无法推进成人型 SMA 的有效诊断:讨论:更新 SMA 诊断的最佳实践建议,将 SMA NBS 的实施纳入其中,对于促进 SMA 患者的护理至关重要。除检测外,有效管理新生儿筛查阳性的流程、获得知识渊博、技术娴熟的医疗保健提供者的服务以及获得治疗方案对于成功的早期诊断至关重要。需要更多证据来改进成人型 SMA 的诊断。
期刊介绍:
Neurology® Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. The journal publishes original articles in all areas of neurogenetics including rare and common genetic variations, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease genes, and genetic variations with a putative link to diseases. Articles include studies reporting on genetic disease risk, pharmacogenomics, and results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology® Genetics, but studies using model systems for treatment trials, including well-powered studies reporting negative results, are welcome.